Last reviewed 2026-04-20 · How we verify

IMETELSTAT SODIUM

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue
• Decreased platelets
• Decreased white blood cells
• Decreased neutrophils
• Increased AST
• Increased alkaline phosphatase
• Increased ALT
• Prolonged partial thromboplastin time
• Arthralgia/myalgia
• COVID-19 infections
• Headache

Serious adverse events

• Sepsis
• Fracture
• Cardiac failure
• Hemorrhage
• Neutropenia
• Thrombocytopenia
• Febrile neutropenia
• Gastrointestinal hemorrhage
• Hypertension
• Infusion-related reactions

Key clinical trials

• A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (PHASE1)
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis (PHASE1)
• Imetelstat Combinations in Relapsed AML (PHASE1)
• Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (PHASE2, PHASE3)
• A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment (PHASE3)
• Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (PHASE2)
• Expanded Access for Treatment With Imetelstat
• Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.